Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRAMMATIC: Daratumumab/rHuPH20 + Lenalidomide vs Lenalidomide Maintenance in Multiple Myeloma
NCT04071457Phase 3Active, not recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Aug 2019
- Primary completion
- Sep 2032
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of Darzalex Faspro in multiple myeloma (MM) (6 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Overall Survival at 15 years. Started Aug 2019; status: active, not recruiting.
02
Drugs
Darzalex Faspro
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04071457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04071457.